

Anti-angiogénèse avec Avastin

La force des données

9 Essais pivots positifs dans 5 différentes tumeurs (1-2-3-4-5-6-7-8-9)



Roche



1. Study 2107 (avelumab): Horwitz H et al. N Engl J Med. 2014.
2. Study E2201 (nivolumab/Ipilimumab): Gutzmer B et al. J Clin Oncol. 2013.
3. Study MD101666 (first-line/second-line): Subiz I et al. J Clin Oncol. 2014.
4. TME Study MD10147: Benzonana J et al. Lancet Oncol. 2013.
5. AVAIL (first-line/second-line): Miller K et al. N Engl J Med. 2015.
6. E2100 (first-line/second-line): Miller K et al. N Engl J Med. 2015.
7. ICON7 (second-line): Perron T et al. N Engl J Med. 2011.
8. COLEMAN (second-line, platinum sensitive): Aghajanian C et al. J Clin Oncol. 2012.
9. Imatinib 415 et al. J Clin Oncol. 2009; 27:4731-4740.



AVASTIN[®]
bevacizumab